Medicare Part D coverage · rifaximin · RxCUI 539789

rifaximin 200 MG Oral Tablet [XIFAXAN]

Per the CMS 2026 Part D formulary file, rifaximin 200 MG Oral Tablet [XIFAXAN] is covered by 2,798 Medicare Part D plans (55.4% of enrollable products), averaging Tier 3.1, with prior authorization required on 89.9% of covering formularies.

55.4%
Plan coverage
2,798
Plans covering
T3.1
Avg tier
89.9%
Prior auth required

Verify with CMS →

Important: Drug coverage and costs vary by plan and location. Verify coverage directly with your Medicare plan before filling a prescription. This is informational data only and should not replace advice from your healthcare provider or pharmacist.

What the CMS Formulary Data Shows for rifaximin 200 MG Oral Tablet [XIFAXAN]

Per the CMS 2026 Part D formulary file, rifaximin 200 MG Oral Tablet [XIFAXAN] (RxNorm concept RXCUI 539789, generic name rifaximin) appears on 168 distinct formulary files spanning 2,798 Medicare Part D plan offerings - 55.4% of enrollable Part D products, mid-range placement; shopping across contracts changes access. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 3.1.

Real-world access to rifaximin 200 MG Oral Tablet [XIFAXAN] depends on utilization management as much as tier placement: 89.9% of covering formularies require prior authorization. 0% require step therapy. 72.6% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 96,011 Part D beneficiaries filled rifaximin 200 MG Oral Tablet [XIFAXAN] in 2023, with total plan-and-beneficiary spending of $1,090,110,101 and an average per-beneficiary annual cost of $11,354.01. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry rifaximin 200 MG Oral Tablet [XIFAXAN] today.

Coverage Details

Formularies covering
168
Plans covering
2,798
Coverage rate
55.4%
Tier range
Tier 1 – Tier 4
Average tier
Tier 3, Preferred Brand

Restrictions

Prior authorization required
89.9% of formularies
Step therapy required
0% of formularies
Quantity limits
72.6% of formularies

2023 Medicare Spending

Beneficiaries
96,011
Total spending
$1,090,110,101
Avg per beneficiary
$11,354.01

Tier Distribution Across Plans

66 plans
Tier 1, Preferred Generic
6 plans
Tier 2, Generic
28 plans
Tier 3, Preferred Brand

Medicare Advantage Plans (MA-PD) Covering rifaximin 200 MG Oral Tablet [XIFAXAN]

100 Medicare Advantage plans with Part D drug coverage include this drug.

Plan Insurer Tier PA Premium States
Sentara Community Complete Select (HMO D-SNP) Sentara Health Plans T1 Yes $0 VA
Sentara Community Complete (HMO D-SNP) Sentara Health Plans T1 Yes $0 VA
ElderServe MAP (HMO D-SNP) Elderserve Health, Inc. T1 Yes $0 NY
Cooperative Advantage (HMO D-SNP) Group Health Cooperative OF EAU Claire T1 Yes $0 WI
Longevity Health Plan (PPO I-SNP) Longevity Health Plan OF NEW Jersey Insurance Comp T1 Yes $0 NJ
Upper Peninsula Health Plan MI Coordinated Health (HMO D-SNP) Upper Peninsula Health Plan, LLC T1 Yes $0 MI
CareSource Dual Advantage (HMO D-SNP) Caresource Georgia Co. T1 Yes $0 GA
HAP CareSource MI Coordinated Health (HMO D-SNP) HAP Caresource T1 Yes $0 MI
SeniorCare Complete (HMO D-SNP) South Country Health Alliance T1 Yes $0 MN
AbilityCare (HMO D-SNP) South Country Health Alliance T1 Yes $0 MN
Alameda Alliance Wellness (HMO D-SNP) Alameda Alliance FOR Health T1 Yes $0 CA
Elevate Medicare Choice (HMO D-SNP) Denver Health Medical Plan, Inc. T1 Yes $0 CO
AllCare Advantage Redwood Rx (HMO D-SNP) Allcare Health Plan, Inc. T1 Yes $0 OR
PrimeWest Senior Health Complete (HMO D-SNP) Primewest Rural MN Health Care Access Initiative T1 Yes $0 MN
Prime Health Complete (HMO D-SNP) Primewest Rural MN Health Care Access Initiative T1 Yes $0 MN
Alterwood Advantage Dual Secure (HMO D-SNP) Alterwood Advantage, Inc. T1 Yes $0 MD
Nascentia Dual Advantage (HMO D-SNP) Visiting Nurse Association OF Central NEW York T1 Yes $0 NY
Provider Partners Pennsylvania Community Plan (HMO I-SNP) Provider Partners Health Plan OF Pennsylvania, Inc T1 Yes $0 PA
Provider Partners North Carolina Community Plan (HMO I-SNP) Provider Partners Health Plan OF North Carolina T1 Yes $0 NC
Provider Partners Indiana Community Plan (HMO I-SNP) Provider Partners Health Plan OF Indiana T1 Yes $0 IN
Show the next 30 plans
Provider Partners Missouri Community Plan (HMO I-SNP) Provider Partners Health Plan OF Missouri, Inc. T1 Yes $0 MO
Abilis Health Community (HMO I-SNP) Signature Advantage, LLC T1 Yes $0 KY, TN
Arkansas Integrated Providers (AIP) Dual Advantage (HMO D-SNP) Arkansas Superior Select, Inc. T1 Yes $0 AR
Community Care's Partnership Program (HMO D-SNP) Community Care Health Plan, Inc. T1 No $0 WI
Mass General Brigham SCO (HMO D-SNP) Mass General Brigham Health Plan, Inc T1 Yes $0 MA
Mass General Brigham One Care (HMO D-SNP) Mass General Brigham Health Plan, Inc T1 Yes $0 MA
Highmark Wholecare Medicare Assured Diamond (HMO D-SNP) Gateway Health Plan, Inc. T1 Yes $0 PA
Highmark Wholecare Medicare Assured Diamond (HMO D-SNP) Gateway Health Plan, Inc. T1 Yes $0 PA
Highmark Health Options Duals (HMO D-SNP) Highmark Health Options West Virginia Inc. T1 Yes $0 WV
Highmark Health Options Duals (HMO D-SNP) Highmark Bcbsd, Inc. T1 Yes $0 DE
Longevity Health Plan (HMO I-SNP) Longevity Health Plan OF Florida, Inc. T1 Yes $4.80 FL
Gold Dialysis & Kidney Complete (HMO-POS C-SNP) Gold Kidney OF Florida Inc T1 Yes $4.80 FL
Provider Partners Texas Advantage Plan (HMO I-SNP) Provider Partners Health Plan OF Texas, Inc. T1 Yes $4.80 TX
Texas Independence Health Plan, Inc. (HMO I-SNP) Texas Independence Health Plan, Inc. T1 Yes $4.80 TX
Texas Independence Community Plan (HMO I-SNP) Texas Independence Health Plan, Inc. T1 Yes $4.80 TX
Longevity Health Plan (HMO I-SNP) Longevity Health Plan OF Michigan, Inc. T1 Yes $8.80 MI
Tribute Select (HMO-POS I-SNP) Arkansas Superior Select, Inc. T1 Yes $8.90 AR
ATRIO Special Needs Plan (HMO D-SNP) Atrio Health Plans T1 Yes $10.50 OR
ATRIO Special Needs Plan (HMO D-SNP) Atrio Health Plans T1 Yes $10.50 OR
Highmark Wholecare Medicare Assured Ruby (HMO D-SNP) Gateway Health Plan, Inc. T1 Yes $13.10 PA
Longevity Health Plan (HMO I-SNP) Longevity Health Plan OF Illinois, Inc. T1 Yes $15.20 IL
Provider Partners Illinois Advantage Plan (HMO I-SNP) Provider Partners Health Plan OF Illinois T1 Yes $15.20 IL
Gold Dialysis & Kidney Complete (HMO-POS C-SNP) Gold Kidney OF Arizona T1 Yes $17.00 AZ
Highmark Wholecare Medicare Assured Ruby (HMO D-SNP) Gateway Health Plan, Inc. T1 Yes $17.60 PA
WellSense Added Value (HMO) Boston Medical Center Health Plan, Inc. T1 Yes $21.70 NH
Alterwood Advantage Dual Value (HMO D-SNP) Alterwood Advantage, Inc. T1 Yes $31.20 MD
Highmark Health Options Duals Select (HMO D-SNP) Highmark Bcbsd, Inc. T1 Yes $31.20 DE
Valor Health Plan (HMO I-SNP) TSG Guard, Inc. T1 Yes $31.40 OH
Provider Partners Pennsylvania Advantage Plan (HMO I-SNP) Provider Partners Health Plan OF Pennsylvania, Inc T1 Yes $32.70 PA
Provider Partners Pennsylvania Essential Plan (HMO I-SNP) Provider Partners Health Plan OF Pennsylvania, Inc T1 Yes $32.70 PA

Showing top 50 of 100 plans.

Frequently Asked Questions

Is rifaximin 200 MG Oral Tablet [XIFAXAN] covered by Medicare Part D?

Yes, rifaximin 200 MG Oral Tablet [XIFAXAN] is covered by 2,798 Medicare Part D plans (55.4% of all Part D formularies).

What tier is rifaximin 200 MG Oral Tablet [XIFAXAN] on Medicare Part D plans?

rifaximin 200 MG Oral Tablet [XIFAXAN] averages Tier 3.1 across Part D plans, ranging from Tier 1 to Tier 4.

Does rifaximin 200 MG Oral Tablet [XIFAXAN] require prior authorization?

89.9% of Part D formularies require prior authorization for rifaximin 200 MG Oral Tablet [XIFAXAN]. Step therapy: 0%. Quantity limits: 72.6%.

How much does Medicare spend on rifaximin 200 MG Oral Tablet [XIFAXAN]?

In 2023, total Medicare Part D spending on rifaximin 200 MG Oral Tablet [XIFAXAN] was $1,090,110,101, covering 96,011 beneficiaries. The average spend per beneficiary was $11,354.01.

Nationwide similar Part D drugs

Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.

Data sourced from the Centers for Medicare & Medicaid Services (CMS). See our methodology for details. Retrieved and formatted by PlainMedicare